In addition, 3,196,737 people have received the second dose on and other 3,833,448 the first one.
Previous figures add up to 9,650,235 applied doses in different modalities: health intervention and clinical trials, Dr. Duran stated.
Abdala vaccine, one of the candidates applied in the national immunization strategy, was approved for emergency use by the national regulatory authority on July 9 and thus became the first anti-COVID-19 product developed in Latin America.
Created by the Center for Genetic Engineering and Biotechnology (CIGB), Abdala candidate provides a three-dose immunization scheme, proving a 92.28% effectiveness in its phase III of its clinical trials
On the other hand, Soberana 02 candidate –created by the Finlay Vaccine Institute (IFV)– also used for national immunization, together with Soberana PLUS proposal, proved 91.2% effectiveness in phase III of its clinical trials.